Instrument Inactif

Communiqués Neon Therapeutics, Inc.

Actions

US64050Y1001

Recherche biotechnologique et médicale

Communiqués

06/05/20	NEON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
05/05/20	NEON THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
30/04/20	Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	GL
29/04/20	NEON THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
02/03/20	NEON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
02/03/20	NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
02/03/20	Neon Therapeutics : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update	AQ
29/01/20	NEON THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neon Therapeutics, Inc. - NTGN	BU
16/01/20	NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
18/12/19	Neon Therapeutics : Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	AQ
20/11/19	NEON THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (form 8-K)	AQ
20/11/19	Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs	GL
12/11/19	Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights	GL
08/11/19	Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting	GL
05/09/19	Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens	GL
06/08/19	Neon Therapeutics Reports Second Quarter 2019 Financial Results	GL
15/07/19	Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers	GL
03/06/19	Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference	GL
13/05/19	Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update	GL
31/03/19	Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting	GL
04/03/19	Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference	GL
28/02/19	Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting	GL
21/02/19	Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference	GL
06/12/18	Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma	GL
16/11/18	Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe	GL